AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Feb 2022
Historique:
received: 20 01 2022
revised: 02 02 2022
accepted: 04 02 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 17 2 2022
Statut: epublish

Résumé

Preventing the cytokine storm observed in COVID-19 is a crucial goal for reducing the occurrence of severe acute respiratory failure and improving outcomes. Here, we identify Aldo-Keto Reductase 1B10 (AKR1B10) as a key enzyme involved in the expression of pro-inflammatory cytokines. The analysis of transcriptomic data from lung samples of patients who died from COVID-19 demonstrates an increased expression of the gene encoding AKR1B10. Measurements of the AKR1B10 protein in sera from hospitalised COVID-19 patients suggests a significant link between AKR1B10 levels and the severity of the disease. In macrophages and lung cells, the over-expression of AKR1B10 induces the expression of the pro-inflammatory cytokines Interleukin-6 (

Identifiants

pubmed: 35163833
pii: ijms23031911
doi: 10.3390/ijms23031911
pmc: PMC8836815
pii:
doi:

Substances chimiques

Cytokines 0
Enzyme Inhibitors 0
AKR1B10 protein, human EC 1.1.1.-
Aldo-Keto Reductases EC 1.1.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : French National Cancer Institute
ID : INCa_13641

Références

PLoS One. 2018 Oct 31;13(10):e0205747
pubmed: 30379862
Front Pharmacol. 2020 Sep 15;11:584057
pubmed: 33041827
Nat Commun. 2020 Dec 4;11(1):6208
pubmed: 33277494
Lancet Reg Health Am. 2021 Oct;2:100062
pubmed: 34485970
Sci Rep. 2021 Mar 29;11(1):7052
pubmed: 33782412
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Lancet Respir Med. 2021 Dec;9(12):1439-1449
pubmed: 34599903
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Cells. 2021 Jun 30;44(6):408-421
pubmed: 34059561
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
J Clin Endocrinol Metab. 2015 Jun;100(6):2231-8
pubmed: 25885947
Innate Immun. 2012 Feb;18(1):80-8
pubmed: 21239457
Biomol Concepts. 2011 Apr 1;2(1-2):103-114
pubmed: 21547010
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
FASEB J. 2004 Aug;18(11):1209-18
pubmed: 15284221
Metabolites. 2021 May 21;11(6):
pubmed: 34063865
Acta Biomater. 2019 Jun;91:195-208
pubmed: 31034948
Chem Biol Interact. 2011 May 30;191(1-3):339-45
pubmed: 21334316
Drug Metab Rev. 2008;40(4):553-624
pubmed: 18949601
Eur J Pharmacol. 2008 Apr 28;584(2-3):213-21
pubmed: 18325492
Hepatology. 2019 Jun;69(6):2489-2501
pubmed: 30672601
Theranostics. 2022 Jan 1;12(1):207-231
pubmed: 34987642
J Biol Chem. 2013 Dec 20;288(51):36733-40
pubmed: 24217247
Chest. 2021 Mar;159(3):1019-1040
pubmed: 33129791
J Gastroenterol. 2019 Jun;54(6):549-557
pubmed: 30707282
Eur J Pharmacol. 2021 Apr 15;897:173926
pubmed: 33549577
Transl Gastroenterol Hepatol. 2020 Apr 05;5:16
pubmed: 32258520
Trends Immunol. 2021 Aug;42(8):681-705
pubmed: 34217595
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5395-403
pubmed: 17122129
Chem Biol Interact. 2011 May 30;191(1-3):330-8
pubmed: 21354119
QJM. 2021 Dec 20;114(10):721-732
pubmed: 34570241
Signal Transduct Target Ther. 2021 Jul 7;6(1):255
pubmed: 34234112
Virus Res. 2007 Sep;128(1-2):1-8
pubmed: 17532082
Inflamm Allergy Drug Targets. 2013 Jun;12(3):178-86
pubmed: 23360251
ACS Appl Mater Interfaces. 2022 Jan 26;14(3):4714-4724
pubmed: 35081679
Cell Stress Chaperones. 2014 Mar;19(2):281-7
pubmed: 23975544
Sci Rep. 2015 Nov 30;5:17319
pubmed: 26616523
Cell Biol Int. 2020 Sep;44(9):1792-1797
pubmed: 32458561
Proc Am Thorac Soc. 2009 Dec;6(8):697-700
pubmed: 20008878

Auteurs

Clovis Chabert (C)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Anne-Laure Vitte (AL)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Domenico Iuso (D)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Florent Chuffart (F)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Candice Trocme (C)

Laboratoire BEP (Biochimie des Enzymes et les Protéines), Institut de Biologie et de Pathologie, CHU Grenoble Alpes, 38700 La Tronche, France.

Marlyse Buisson (M)

Institut de Biologie Structurale, CEA, CNRS and Centre Hospitalier Universitaire Grenoble Alpes, Université Grenoble Alpes, 38000 Grenoble, France.

Pascal Poignard (P)

Institut de Biologie Structurale, CEA, CNRS and Centre Hospitalier Universitaire Grenoble Alpes, Université Grenoble Alpes, 38000 Grenoble, France.

Benjamin Lardinois (B)

Laboratory Department, CHU UCL Namur Site de Ste Elisabeth, 5000 Namur, Belgium.

Régis Debois (R)

Laboratory Department, CHU UCL Namur Site de Ste Elisabeth, 5000 Namur, Belgium.

Sophie Rousseaux (S)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Jean-Louis Pepin (JL)

HP2 Laboratory, INSERM U1300, Grenoble Alpes University, 38000 Grenoble, France.
Sleep Laboratory, Pole Thorax et Vaisseaux, Grenoble Alpes University Hospital, 38000 Grenoble, France.

Jean-Benoit Martinot (JB)

Sleep Laboratory and Pulmonology and Allergy Department-CHU UCL Namur, St. Elisabeth Site, 5000 Namur, Belgium.
Institute of Experimental and Clinical Research, UCL Bruxelles Woluwe, 1200 Brussels, Belgium.

Saadi Khochbin (S)

Institute for Advanced Biosciences-UGA-INSERM U1209-CNRS UMR 5309, 38700 La Tronche, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH